Cargando…
VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients
BACKGROUND: Peritoneal dissemination and retroperitoneal lymph node involvement are main routes for progression of epithelial ovarian cancer (EOC). Vascular endothelial growth factor (VEGF) mediated angiogenesis has been identified as an important mechanism promoting tumour progression. METHODS: Tum...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522140/ https://www.ncbi.nlm.nih.gov/pubmed/28591727 http://dx.doi.org/10.18632/oncotarget.17978 |
_version_ | 1783252109671530496 |
---|---|
author | Kuerti, Sascha Oliveira-Ferrer, Leticia Milde-Langosch, Karin Schmalfeldt, Barbara Legler, Karen Woelber, Linn Prieske, Katharina Mahner, Sven Trillsch, Fabian |
author_facet | Kuerti, Sascha Oliveira-Ferrer, Leticia Milde-Langosch, Karin Schmalfeldt, Barbara Legler, Karen Woelber, Linn Prieske, Katharina Mahner, Sven Trillsch, Fabian |
author_sort | Kuerti, Sascha |
collection | PubMed |
description | BACKGROUND: Peritoneal dissemination and retroperitoneal lymph node involvement are main routes for progression of epithelial ovarian cancer (EOC). Vascular endothelial growth factor (VEGF) mediated angiogenesis has been identified as an important mechanism promoting tumour progression. METHODS: Tumour tissue of 100 patients with EOC was analysed for protein expression of vascular endothelial growth factor (VEGF)-A, -C, -D by Western Blot analysis. Expression patterns in patients with ‘extensive intraperitoneal’ metastases (pT3c pN1 and pT3b-pT3c pN0, n=80) were compared to patients with ‘predominantly retroperitoneal’ metastases (pT1a-pT3b, pN1, n=20). Overall and progression-free survival was analysed by Kaplan-Meier method. RESULTS: While no significant differences in expression levels among the different modes of metastases were noted for VEGF-A and -D, VEGF-C expression was significantly higher in the group of predominantly retroperitoneal metastases compared to the group with extensive intraperitoneal metastases. Patients with high VEGF-C expression had a significantly worse overall survival compared to patients with low expression levels. CONCLUSIONS: Retroperitoneal tumour progression in EOC patients is associated with high VEGF-C expression. VEGF-C may serve as a molecular marker to identify patients with assumed high risk for lymphatic metastases, who might benefit from specific treatment strategies. |
format | Online Article Text |
id | pubmed-5522140 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-55221402017-08-08 VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients Kuerti, Sascha Oliveira-Ferrer, Leticia Milde-Langosch, Karin Schmalfeldt, Barbara Legler, Karen Woelber, Linn Prieske, Katharina Mahner, Sven Trillsch, Fabian Oncotarget Research Paper BACKGROUND: Peritoneal dissemination and retroperitoneal lymph node involvement are main routes for progression of epithelial ovarian cancer (EOC). Vascular endothelial growth factor (VEGF) mediated angiogenesis has been identified as an important mechanism promoting tumour progression. METHODS: Tumour tissue of 100 patients with EOC was analysed for protein expression of vascular endothelial growth factor (VEGF)-A, -C, -D by Western Blot analysis. Expression patterns in patients with ‘extensive intraperitoneal’ metastases (pT3c pN1 and pT3b-pT3c pN0, n=80) were compared to patients with ‘predominantly retroperitoneal’ metastases (pT1a-pT3b, pN1, n=20). Overall and progression-free survival was analysed by Kaplan-Meier method. RESULTS: While no significant differences in expression levels among the different modes of metastases were noted for VEGF-A and -D, VEGF-C expression was significantly higher in the group of predominantly retroperitoneal metastases compared to the group with extensive intraperitoneal metastases. Patients with high VEGF-C expression had a significantly worse overall survival compared to patients with low expression levels. CONCLUSIONS: Retroperitoneal tumour progression in EOC patients is associated with high VEGF-C expression. VEGF-C may serve as a molecular marker to identify patients with assumed high risk for lymphatic metastases, who might benefit from specific treatment strategies. Impact Journals LLC 2017-05-18 /pmc/articles/PMC5522140/ /pubmed/28591727 http://dx.doi.org/10.18632/oncotarget.17978 Text en Copyright: © 2017 Kuerti et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Kuerti, Sascha Oliveira-Ferrer, Leticia Milde-Langosch, Karin Schmalfeldt, Barbara Legler, Karen Woelber, Linn Prieske, Katharina Mahner, Sven Trillsch, Fabian VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients |
title | VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients |
title_full | VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients |
title_fullStr | VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients |
title_full_unstemmed | VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients |
title_short | VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients |
title_sort | vegf-c expression attributes the risk for lymphatic metastases to ovarian cancer patients |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522140/ https://www.ncbi.nlm.nih.gov/pubmed/28591727 http://dx.doi.org/10.18632/oncotarget.17978 |
work_keys_str_mv | AT kuertisascha vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients AT oliveiraferrerleticia vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients AT mildelangoschkarin vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients AT schmalfeldtbarbara vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients AT leglerkaren vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients AT woelberlinn vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients AT prieskekatharina vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients AT mahnersven vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients AT trillschfabian vegfcexpressionattributestheriskforlymphaticmetastasestoovariancancerpatients |